ArticleFrontiers in oncology2025
Combining radiomics and deep learning to predict liver metastasis of gastric cancer on CT image.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophage morphology in the tumor microenvironment predicts metachronous liver metastasis in gastric cancer: establishment and validation of a predictive model.Frontiers in immunology · 2026Article
- AI-assisted segmentation-based fusion model integrating deep learning, radiomics, and clinical parameters for identifying coronary heart disease risk in patients with MAFLD.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Our study aimed to explore the potential of deep learning (DL) radiomics features from CT images of primary gastric cancer (GC) in predicting gastric cancer liver metastasis (GCLM) by establishing and verifying a prediction model based on clinical factors, classical radiomics and DL features. Methods: We retrospectively analyzed 1001 pathologically confirmed GC patients from June 2014 to May 2024, divided into non-LM (n=689) and LM groups (n=312). CT-based classic radiomics and DL features were extracted and screened to construct a DL-radiomics score. This score, along with statistically significant clinical factors, was used to build a fused model which visualized as a nomogram. The model's predictive performance, calibration, and clinical utility were assessed and compared against a clinical model. Additionally, the DL-radiomics score's role in distinguishing between synchronous and metachronous GCLM was evaluated. Results: The fused model showed good predictive performance [AUC: 0.796 (95% CI: 0.766-0.826) in training cohort and 0.787 (95% CI: 0.741-0.834) in test cohort], outperforming the clinical model, radiomics score and DL score (P<0.05). In addition, the decision curve confirmed that the model provided the largest clinical net benefit compared with all other models in the relevant threshold. DL-radiomics score showed moderate predictive performance in distinguishing between synchronous GCLM and metachronous GCLM, with an AUC of 0.665 (95% CI, 0.613-0.718). Conclusion: The CT-based fused model has demonstrated significant value in predicting the occurrence of GCLM, and can provide a reference for the personalized follow-up and treatment of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.